Health Canada has added Parsol Shield (Bemotrizinol) to the Secondary Sunscreen Monograph at concentrations up to 6%. The approval marks a significant regulatory advancement for sun protection technologies across cosmetic and multifunctional products, according to dsm-firmenich.

Parsol Shield has been permitted under Canada’s Primary Sunscreen Monograph. The updated monograph permits the UVA/UVB filter in a wider array of formulations where sun protection plays a secondary role, such as popular daily-wear cosmetics and multifunctional skincare products. 

“This milestone aligns with dsm-firmenich’s ongoing efforts in the United States to secure FDA approval of Parsol Shield as a sunscreen active ingredient. Health Canada’s decision to update the monograph reflects a strengthened industry alignment and reinforces the strong safety and efficacy profile of Parsol Shield as a highly photostable, broad‑spectrum UVA/UVB filter” said Amy Ethier, PhD, regulatory affairs manager North America, Beauty and Care.

Issued in December 2025, the updated monograph will enable broader use of Parsol Shield in sunscreen‑containing products sold in Canada. This regulatory progression, according to dsm-firmenich, supports its commitment to advancing high-performance UV filters while expanding market opportunities for its customers.